BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 17008305)

  • 1. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
    Lanas A; Hunt R
    Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
    Lanas A; Scheiman J
    Curr Med Res Opin; 2007 Jan; 23(1):163-73. PubMed ID: 17257477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L
    Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
    Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
    Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
    Sostres C; Gargallo CJ; Arroyo MT; Lanas A
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):121-32. PubMed ID: 20227026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
    McCarthy DM
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Spiegel BM; Chiou CF; Ofman JJ
    Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.